Battle Motors Picks T-Mobile to Connect New RevolutionOS™ EV Software for Trucks
9.5.2022 16:19:00 EEST | Business Wire | Press release
Today, T-Mobile (NASDAQ: TMUS) announced that Battle Motors has selected the Un-carrier as the preferred provider of IoT connectivity and management for thousands of new Battle Motors battery electric trucks rolling off the Ohio-based production line. And these trucks are getting smarter, thanks to Battle Motors' all new factory installed RevolutionOS™ EV software.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220509005589/en/
Battle Motors Picks T‑Mobile to Connect New RevolutionOS™ EV Software for Trucks. IoT connectivity and management powers heavy‑duty technology to electrify the commercial truck industry. (Graphic: Business Wire)
Like consumer automotive, the commercial truck industry is moving swiftly to embrace EV technology — and Battle Motors is no exception. Their RevolutionOS™, powered by T-Mobile's nationwide network, delivers actionable data and information to drivers and fleet managers that they can use to enhance efficiency, safety, and security. As part of this long-term agreement, T-Mobile for Business will deliver 4G LTE connectivity to Battle Motors trucks for near real-time sharing of battery range and usage information, historic and near real-time location and trip data, timely preventative maintenance warnings, over-the-air software, and firmware updates — as well as the truck's full bill of materials, such as VIN-specific information, parts, and manuals.
Every new Battle Motors class seven and class eight "heavy-duty" EV truck — like the ones that haul garbage, dirt, and freight — will come with a factory installed, ruggedized digital instrument cluster that runs RevolutionOS™. And thanks to the power and reliability of T-Mobile's nationwide network, Battle Motors’ RevolutionOS™ will let customers view and update critical information directly from the truck, or remotely from a desktop computer or mobile device, just by scanning a QR code!
Additionally, T-Mobile Control Center will give Battle Motors the ability to view and manage the connectivity of their trucks. With the automation and provisioning capabilities of T-Mobile’s IoT platform, Battle Motors can easily accelerate deployment of their growing line of trucks. Battle Motors will have near real-time visibility to all their commercial trucks with the ability to monitor network conditions and device behavior with T-Mobile Control Center.
In the near future, Battle Motors expects to leverage the Un-carrier's 5G network to meet industrial-sized challenges for years to come as their trucks’ capabilities advance and the demands on connectivity increase. T-Mobile is poised to push IoT to its full potential and catapult adoption — paving the way for new electric vehicle applications that rely on low-latency, high-speed data, and real-time location and proximity-based services.
“Our primary focus has been on driving technology and innovation that gives our customers value and peace-of-mind when it comes to maintenance, efficiency, safety and compliance,” says Battle Motors CSO, Paul Marsolan. “Together with T-Mobile, we’re able to merge analytics and operations to put rich, real-time decision-making data to work for our customers.”
“While we continue to grow our business market share, it energizes us to work with forward thinking companies that demonstrate leadership in areas like sustainable commercial transportation,” said Callie Field, President, T-Mobile Business Group. “Reliable connectivity, management and support is central to Battle Motors’ mission, and we’re honored that they entrusted their trucks and their customers to T-Mobile for Business.”
For more information about IoT from T-Mobile for Business, visit www.t-mobile.com/business/solutions/iot.
To find out more about Battle Motors, go to www.battlemotors.com.
About T-Mobile
T-Mobile U.S. Inc. (NASDAQ: TMUS) is America’s supercharged Un-carrier, delivering an advanced 4G LTE and transformative nationwide 5G network that will offer reliable connectivity for all. T-Mobile’s customers benefit from its unmatched combination of value and quality, unwavering obsession with offering them the best possible service experience and undisputable drive for disruption that creates competition and innovation in wireless and beyond. Based in Bellevue, Wash., T-Mobile provides services through its subsidiaries and operates its flagship brands, T-Mobile, Metro by T-Mobile and Sprint. For more information please visit: https://www.t-mobile.com.
About Battle Motors
Battle Motors, a leader in the development of electric vehicle (EV) technology, acquired commercial vehicle Original Equipment Manufacturer (OEM), Crane Carrier Company, LLC (CCC) in 2021. Battle Motors is the leader in the vocational truck industry, providing work-ready diesel, clean natural gas (CNG), and now EV chassis designed and manufactured in North America for the refuse and recycling markets. Battle Motor’s durable, dependable trucks are built to excel in a multitude of applications that now include middle-mile and last-mile delivery. CCC has been manufacturing commercial vehicles for 75 years and is based in New Philadelphia, Ohio. For more information please visit: https://www.battlemotors.com and follow us @BattleMotors
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220509005589/en/
Contact information
Media Contacts
T-Mobile US, Inc. Media Relations
MediaRelations@t-mobile.com
Investor Relations Contact
T-Mobile US, Inc.
investor.relations@t-mobile.com
https://investor.t-mobile.com
Media Contact for Battle Motors | RevolutionOS
Jennifer Gross
Jennifer@Battlemotors.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
